Research
Filter News
Found 142,651 articles
-
Quest Diagnostics Extends Alzheimer's Disease Portfolio with New AI-Powered Test Service from uMETHOD Health
5/4/2023
Quest Diagnostics today announced nationwide availability of the RestoreU ™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline.
-
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
5/4/2023
MaxCyte, Inc. today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics , Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics.
-
TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases
5/4/2023
TFF Pharmaceuticals, Inc. today announced that it has entered into a Collaborative Research and Development Agreement (CRADA) with the National Institute of Environmental Health Sciences (NIEHS) to develop respirable, dry powder formulations of high molecular weight hyaluronan (HMW-HA) for treating or preventing respiratory diseases.
-
Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
5/4/2023
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended March 31, 2023.
-
Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant
5/4/2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to support a Phase 1 clinical trial with TNX-1500 (anti-CD40L monoclonal antibody [mAb]).
-
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
5/4/2023
Silence Therapeutics plc today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program.
-
Henry Schein Signs Definitive Agreement to Acquire S.I.N. Implant System
5/4/2023
Henry Schein, Inc. announced an agreement to acquire S.I.N. Implant System, one of Brazil’s leading manufacturers of dental implants, pending regulatory approval.
-
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
5/4/2023
CHMP Adopts Positive Opinion Recommending Hepcludex ® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV).
-
Brain Cancer Canada Awards CAD 50,000 Grant for Innovative Research to Improve Brain Cancer Diagnosis and Treatment
5/4/2023
Brain Cancer Canada is pleased to announce a $50,000 grant to support research on more effective diagnosis and treatment for adult brain cancer patients.
-
Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
5/4/2023
Theratechnologies Inc. today presented data from a landmark study in which the use of ibalizumab, a monoclonal antibody antiretroviral therapy (ART) commercialized as Trogarzo®, was associated with favorable virologic outcomes compared to non-ibalizumab regimens used in routine care in heavily treatment-experienced people with HIV.
-
Fluent BioSciences Releases Comprehensive White Paper Highlighting Increased Performance Metrics with the Latest v4.0 PIPseq Single Cell RNA Sequencing Kits
5/4/2023
Fluent BioSciences has published a white paper highlighting the performance improvements of the recently announced v4.0 chemistry as compared to the previous v3.0 chemistry.
-
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
5/4/2023
Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the initiation of Alvotech’s confirmatory patient study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria®.
-
Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering
5/4/2023
Mekonos, Inc. has announced a new research collaboration with bit.bio, a synthetic biology company providing human cells for research, drug discovery and cell therapy.
-
XNK Therapeutics Enters into Research Agreement with Global Pharma Company
5/4/2023
XNK Therapeutics AB announced that the company's autologous natural killer cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company.
-
Artificial intelligence identifies anti-aging drug candidates targeting ‘zombie’ cells
5/4/2023
Integrated Biosciences in collaboration with researchers at the Massachusetts Institute of Technology and the Broad Institute of MIT and Harvard, announced results demonstrating the power of artificial intelligence to discover novel senolytic compounds, a class of small molecules under intense study for their ability to suppress age-related processes such as fibrosis, inflammation and cancer.
-
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets
5/4/2023
Bicycle Therapeutics plc announced that it has entered into a collaboration with the German Cancer Research Center, to develop and discover Bicycle® radio conjugates for a range of oncology targets.
-
Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb
5/4/2023
Amphista Therapeutics today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone.
-
Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)
5/3/2023
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has determined its first two indications in non-small cell lung cancer (NSCLC) in which to pursue Phase III clinical trials for its innovative, potential first-in-class bispecific antibody, ivonescimab.
-
Veracyte Announces Release of Inaugural ESG Report
5/3/2023
Veracyte, Inc. (Nasdaq: VCYT) today announced that it released its inaugural Environmental, Social and Governance (ESG) Report.
-
Kalos Medical Announces Grant Award, Completion of Patient Recruitment of Clinical Trial
5/3/2023
Kalos Medical, Inc. announced that on April 24th it was selected as a participant in the 2023 Industrial Technology Innovation Project, administered by South Korea’s Ministry of Trade, Industry, and Energy.